ReviewJournal of thoracic disease2026
The regulation of oxidative stress response by epigenetic modifications in acute respiratory distress syndrome.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute respiratory distress syndrome (ARDS), a life-threatening condition driven by diffuse alveolar-capillary injury and loss of redox homeostasis, still lacks effective targeted pharmacotherapies. Current management remains predominantly supportive, with lung-protective ventilation as the cornerstone of respiratory care. Although ARDS arises from diverse clinical insults, oxidative stress emerges as a shared pathogenic pathway across etiologies. Excessive reactive oxygen species (ROS) production not only directly injures epithelial and endothelial cells but also perpetuates inflammatory signaling. ROS generation and clearance are compartmentalized, governed by interconnected pathways that span multiple organelles and cellular processes, forming a dynamic redox network that becomes especially vulnerable during critical illness. Growing evidence implicates epigenetic mechanisms as key modulators of this redox-inflammation interface. In this review, we delineate how three pivotal epigenetic processes regulate oxidative stress in ARDS: DNA methylation, histone modifications, and non-coding RNAs. We also examine the crosstalk among these mechanisms and evaluate emerging interventions targeting these pathways, emphasizing both their therapeutic potential and the persistent challenges in clinical translation. Importantly, rather than viewing these mechanisms independently, this review integrates current evidence to highlight epigenetic regulation as a critical layer linking oxidative stress, inflammatory signaling, and cellular injury in ARDS. We further propose that effective therapeutic strategies may require stage-specific and cell-type-oriented modulation of epigenetic targets, rather than uniform systemic inhibition. By synthesizing these insights, this review aims to provide a conceptual framework that may help guide the development of more precise redox-targeted epigenetic interventions in ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.